Key points
- FY26 total sales of US$23.7 million, up 26% year-over-year
- Sales excluding China reached US$22.7 million, up 29% year-over-year
- Achieved positive EBITDA of US$0.14 million in H2FY26
- Group cash outflow from operations reduced to A$0.2 million for the quarter
- FY27 sales, excluding China, expected to be between US$26 million and US$31 million
Full summary
Nova Eye Medical Ltd reported total sales of US$23.7 million for the year ended 30 June 2026, marking a 26% increase year-over-year. Sales excluding China reached US$22.7 million, up 29% year-over-year. The company achieved a positive EBITDA of US$0.14 million in the second half of FY26, ahead of guidance. Group cash outflow from operations reduced to A$0.2 million for the quarter. The company expects sales, excluding China, to be between US$26 million and US$31 million in FY27, with positive EBITDA expected.
Guidance
FY27 sales, excluding China, expected to be between US$26 million and US$31 million
Outlook
Nova Eye Medical Ltd expects continued growth in FY27, with positive EBITDA anticipated. The company's cash position and existing debt facilities are expected to support these growth targets.